Detection of Hepatocellular Carcinoma Using 11C-Choline PET: Comparison with 18F-FDG PET

Yuka Yamamoto1, Yoshihiro Nishiyama1, Reiko Kameyama1, Keiichi Okano2, Hirotaka Kashiwagi2, Akihiro Deguchi3, Masato Kaji4, and Motoomi Ohkawa1

1Department of Radiology, Faculty of Medicine, Kagawa University, Kagawa, Japan; 2Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan; 3Departments of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan; and 4Department of Pharmacy, Kagawa University Hospital, Kagawa, Japan

The purpose of this study was to retrospectively investigate the feasibility of 11C-choline PET, compared with 18F-FDG PET, for the detection of hepatocellular carcinoma (HCC). Methods: A total of 16 HCC lesions in 12 patients were examined with both 11C-choline PET and 18F-FDG PET. Tumor lesions were identified as areas of focally increased uptake, exceeding that of surrounding noncancerous liver tissue. For semiquantitative analysis, the tumor-to-liver (T/L) ratio was calculated by dividing the maximal standardized uptake value (SUV) in HCC lesions by the mean SUV in noncancerous liver tissue. Results: 11C-choline PET showed a slightly higher detection rate than did 18F-FDG PET for detection of HCC (63% vs. 50%, respectively), although this difference was not statistically significant. 11C-choline PET had a better detection rate for moderately differentiated HCC lesions but not for poorly differentiated HCC lesions (75% vs. 25%, respectively). In contrast, 18F-FDG PET exhibited the opposite behavior, with corresponding detection rates of 42% and 75%, respectively. The mean 11C-choline SUV and T/L ratio in moderately differentiated HCC lesions were higher than those in poorly differentiated HCC lesions. In contrast, the mean 18F-FDG SUV and T/L ratio in poorly differentiated HCC were higher than those in moderately differentiated HCC. These differences, however, were also not statistically significant. Conclusion: 11C-choline PET had a better detection rate for moderately differentiated HCC lesions but not for poorly differentiated HCC lesions, whereas 18F-FDG PET produced the opposite result. 11C-choline is a potential tracer to complement 18F-FDG in detection of HCC.

Key Words: 11C-choline; 18F-FDG; PET; hepatocellular carcinoma


DOI: 10.2967/jnumed.108.052639
by a modified method of Toorongian et al. (13). The radiochemical purity of the produced 18F-FDG was greater than 95%.

**PET**

All acquisitions were performed using a scanner (ECAT EXACT HR+; Siemens/CTI Inc.). The imaging system enabled simultaneous acquisition of 63 transverse PET images per field of view (FOV), for a total axial FOV of 15.5 cm. In-plane resolution was approximately 4.6 mm, with an axial resolution of approximately 3.5-mm full width at half maximum. PET scans were performed in the 3-dimensional mode. A transmission scan was obtained using a 68Ge rod source to provide attenuation correction. PET images were reconstructed with ordered-subsets expectation maximization, using 2 iterations and 8 subsets.

Patients were instructed to fast for at least 5 h before the PET scan. For 18F-FDG PET, a normal blood glucose level in the peripheral blood was ensured. Five minutes after an intravenous injection of 11C-choline (6 MBq/kg) or 60 min after an intravenous injection of 18F-FDG (3.5 MBq/kg), attenuation-corrected whole-body scanning was performed from the skull base to the proximal thighs, with 2 and 3 min allowed per bed position for transmission and emission scans, respectively.

The 2 PET scans were acquired within 2 wk. No treatment was performed during this period of PET.

**Data Analysis**

PET and maximum-intensity-projection images were reviewed on a workstation (Sun Microsystems; Siemens/CTI Inc.) in the transverse, coronal, and sagittal planes. Each scan was interpreted independently by 2 experienced nuclear physicians who were unaware of clinical data and information pertaining to the corresponding scan, except for the results of the CT scan. CT scans were assessed for the exact localization of HCC lesions. Any difference of opinion was resolved by consensus.

Tumor lesions were identified as areas of focally increased uptake, exceeding that of surrounding noncancerous liver tissue. For semiquantitative analysis, regions of interest (ROIs) were placed over the entire 11C-choline- or 18F-FDG–avid lesion including the largest amount of radioactivity using the transverse PET image. For HCC lesions not visible on both or either of the 2 PET scans, an ROI was drawn on the respective scans in the region corresponding to the area of abnormality on the CT scan. For the noncancerous liver tissue ROI, a circular 2-cm ROI was placed on the noncancerous liver tissue. The standardized uptake value (SUV) was calculated by using the following formula: SUV = c_d/(d_w), where c_d is the decay-corrected tracer tissue concentration (in Bq/g); d is the injected dose (in Bq); and w is the patient’s body weight (in g). The maximal SUV in the HCC lesion ROI and the mean SUV in the noncancerous liver tissue ROI were calculated for each ROI. As a contrast value, the tumor-to-liver (T/L) ratio was also calculated by dividing the HCC lesions SUV by the noncancerous liver tissue SUV.

**Statistical Analysis**

The detection rates of HCC using 11C-choline and 18F-FDG were compared using the paired χ² test. Differences in semiquantitative parameters were analyzed by a Mann–Whitney U test and Wilcoxon signed rank test for unpaired and paired observations, respectively. Semiquantitative data were expressed as mean ± SD. Differences were considered statistically significant at the level of P < 0.05.

**RESULTS**

A total of 10 patients had a single lesion, and the remaining 2 patients had 3 lesions each. The histologic grade of HCC was moderately differentiated (grade II) in 12 lesions and poorly differentiated (grade III) in 4 lesions. Of all 16 HCC lesions, 8 were detected by 11C-choline PET only, 6 were detected by 18F-FDG PET only, and 2 were detected by both modalities. Figures 1–3 show typical cases of HCC lesion detection by 11C-choline only, by 18F-FDG only, and by both imaging techniques. Although 11C-choline PET showed a slightly higher detection rate than did 18F-FDG PET for detection of HCC (63% vs. 50%), the difference was not statistically significant.

The mean (±SD) 11C-choline SUV was 15.23 ± 5.94 and the mean (±SD) T/L ratio was 1.46 ± 0.60 in all HCC lesions. The means (±SD) of the 18F-FDG SUV and T/L ratio were 4.80 ± 3.00 and 1.78 ± 1.08, respectively, in all HCC lesions. No significant difference was found between the 11C-choline and 18F-FDG T/L ratios in any HCC lesions.

A total of 9 of 12 (75%) moderately differentiated lesions could be visualized by 11C-choline PET, whereas only 5 of 12 (42%) such lesions could be detected by 18F-FDG PET. Thus, 11C-choline PET tended to be more sensitive than did 18F-FDG PET for moderately differentiated HCC lesions, although this difference was not statistically significant. In contrast, only 1 of 4 (25%) poorly differentiated lesions...
could be visualized by $^{11}$C-choline PET, and 3 such lesions (75%) were detected by $^{18}$F-FDG PET. Thus, $^{18}$F-FDG PET tended to be more sensitive than did $^{11}$C-choline PET for poorly differentiated HCC lesions, although this difference was also not statistically significant.

The mean ($\pm$SD) $^{11}$C-choline SUV and T/L ratio in moderately differentiated HCC lesions (16.79 ± 4.92 and 1.58 ± 0.53, respectively) were higher than those in poorly differentiated HCC lesions (10.56 ± 7.01 and 1.09 ± 0.72, respectively), but the differences were not statistically significant. In contrast, the mean ($\pm$SD) $^{18}$F-FDG SUV and T/L ratio in poorly differentiated HCC lesions (7.25 ± 5.37 and 2.61 ± 1.85, respectively) were higher than those in moderately differentiated HCC lesions (3.99 ± 1.33 and 1.50 ± 0.57, respectively), but the differences were not statistically significant.

**DISCUSSION**

In the present study of 12 patients with HCC, $^{11}$C-choline PET showed a slightly higher overall detection rate than did $^{18}$F-FDG PET for detection of HCC lesions (63% vs. 50%, respectively), although this difference was not statistically significant. In particular, for detection of moderately differentiated HCC lesions, the detection rates for $^{11}$C-choline PET and $^{18}$F-FDG PET were 75% versus 42%, respectively. $^{18}$F-FDG PET is a useful diagnostic method for metastatic liver tumors (14). A meta-analysis found excellent sensitivity (96%) and specificity (99%) for $^{18}$F-FDG PET in detecting hepatic metastasis from colorectal cancer (15). For HCC lesions, however, several investigators have shown that the sensitivity of $^{18}$F-FDG PET is not sufficiently high (50%–55%) (2,3,14,16). In the present study, the detection rate was only 50% for detection of HCC lesions by $^{18}$F-FDG PET, which is well in agreement with the results in previous reports (2,3,14,16). The activity of glucose-6-phosphatase is reported to vary widely, according to a differentiation grade of HCC: well-differentiated HCC cells are histologically closer to the normal liver cells than to the undifferentiated types (4,17). Thus, the abundance of glucose-6-phosphatase may render these tumors undetectable. However, a high positive rate of $^{18}$F-FDG accumulation has been reported in undifferentiated HCC lesions (16). Previous studies have also shown that the SUV and T/L ratio using $^{18}$F-FDG PET are significantly higher in poorly differentiated HCC lesions than in well-differentiated and moderately differentiated types and, therefore, reflect the degree of HCC differentiation (4,17). In the present study, a similar tendency was seen with tumor grade, although no statistical significance was detected.

The use of $^{11}$C-choline PET has been reported for the detection of tumors in organs such as the brain and prostate, in which $^{18}$F-FDG lacks sensitivity (5,6). However, to the best of our knowledge, no study has reported on the use of $^{11}$C-choline PET for the evaluation of HCC lesions. The

**FIGURE 2.** Images of 70-y-old woman with poorly differentiated HCC. (A) Transverse CT image with contrast enhancement shows low-density mass in right lobe. (B) Transverse $^{11}$C-choline PET image shows no significant uptake in tumor, compared with surrounding noncancerous liver tissue (SUV, 8.64; T/L ratio, 0.93). (C) Transverse $^{18}$F-FDG PET image shows increased uptake in tumor, compared with surrounding noncancerous liver tissue (SUV, 15.20; T/L ratio, 5.26).

**FIGURE 3.** Images of 58-y-old woman with moderately differentiated HCC. (A) Transverse CT image with contrast enhancement shows low-density mass in right lobe. (B) Transverse $^{11}$C-choline PET image shows increased uptake in tumor, compared with surrounding noncancerous liver tissue (SUV, 13.12; T/L ratio, 1.59). (C) Transverse $^{18}$F-FDG PET image shows slightly increased uptake in tumor, compared with surrounding noncancerous liver tissue (SUV, 4.65; T/L ratio, 1.38).
precise uptake mechanism of 11C-choline in tumor cells is not well known. It has been suggested that tumor cells are characterized by their ability to incorporate choline actively to produce phosphatidylcholine, a cell membrane constituent, to facilitate rapid cell duplication (6). When 11C-choline is incorporated in tumors, it is rapidly phosphorylated (yielding 11C-phosphorylcholine) and chemically trapped inside the cell membranes (6).

In the present study, the overall detection rate of HCC lesions using 11C-choline PET was slightly better than that using 18F-FDG PET. This detection rate appears to be dependent on tumor differentiation, as demonstrated by a higher detection rate for moderately versus poorly differentiated HCC lesions using 11C-choline PET and 18F-FDG PET. These results suggest that the 2 tracers may complement each other in the detection of HCC lesions. Similar findings have been reported using 18F-fluorocholine (18) and 11C-acetate, a tracer assumed to be related to lipid synthesis (19), in HCC lesions. To overcome the limited utility of the 11C tracer due to its short half-life (~20 min), 18F-fluorocholine has been developed. Talbot et al. showed that the sensitivity of 18F-fluorocholine (40%) for the detection of HCC lesions was better than that of 18F-FDG (55.6%) (18). A trend toward a higher 18F-fluorocholine SUV in well-differentiated HCC lesions than in poorly differentiated HCC lesions is demonstrated, although the difference was not statistically significant (18). Ho et al. reported that the overall sensitivity of 11C-acetate (87.3%) for the detection of HCC lesions was better than that of 18F-FDG (47.3%) (19). However, 11C-acetate was not sensitive for the detection of poorly differentiated HCC lesions (19). Furthermore, a statistically significant relationship between tumor differentiation and T/L ratio for 18F-FDG PET and 11C-acetate PET exists (19). Ho et al. also evaluated the sensitivity of metastatic HCC lesions with both 11C-acetate and 18F-FDG, compared with that of 18F-FDG or 11C-acetate alone (20). In their results, dual-tracer PET/CT showed an excellent sensitivity (98%) (18F-FDG-PET/CT had 79%) and 11C-acetate PET/CT had 64%) (20). The detection rate for HCC lesions in the present study was slightly lower than that obtained in these previous studies (18, 19). One of the reasons for this difference may be because of the small sample size and the construction of the sample in the present study versus the previous studies (18, 19). The percentage of well-differentiated HCC lesions in the previous studies was 33%–35% (18, 19), although we had no well-differentiated HCC lesions. Furthermore, because the background 18F-fluorochrome levels in the liver parenchyma are low, areas exhibiting their accumulations can be visualized in good contrast to other areas.

A limitation of the present study was the small size of the sample, in which we had no well-differentiated and very few poorly differentiated HCC lesions. This may explain the lack of statistical significance of differences observed. Three patients had received transcatheter arterial embolization therapy before the PET study. The detection rates of HCC lesions were analyzed using visual, not SUV, analysis. The value of the present data is also limited by the retrospective character of the study. Further prospective studies involving a larger number of patients are required to determine the clinical usefulness of 11C-choline PET for detection of HCC lesions.

CONCLUSION

11C-choline PET had a better detection rate for moderately differentiated HCC lesions but not for poorly differentiated HCC lesions, whereas 18F-FDG PET demonstrated the opposite behavior. The use of 11C-choline as a tracer complementary to 18F-FDG in detection of HCC lesions seems to be a possibility.

REFERENCES

Detection of Hepatocellular Carcinoma Using $^{11}$C-Choline PET: Comparison with $^{18}$F-FDG PET

Yuka Yamamoto, Yoshihiro Nishiyama, Reiko Kameyama, Keiichi Okano, Hirotaka Kashiwagi, Akihiro Deguchi, Masato Kaji and Motoomi Ohkawa

Published online: July 16, 2008.
Doi: 10.2967/jnumed.108.052639

This article and updated information are available at:
http://jnm.snmjournals.org/content/49/8/1245

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml